Lexeo Therapeutics, Inc. Common StockLXEONASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
39.45%
↓ 80% below average
Average (4y)
200.25%
Historical baseline
Range
High:944.77%
Low:0.00%
Volatility
471.8%
High variability
| Period | Value |
|---|---|
| 2024 | 39.45% |
| 2023 | 8.07% |
| 2022 | 8.96% |
| 2021 | 944.77% |
| 2020 | 0.00% |